Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
Nicola Ferri, Massimiliano Ruscica, Maria Giovanna Lupo, Marco Vicenzi, Cesare R. Sirtori, Alberto Corsini
Topics & Concepts
AlirocumabPCSK9EvolocumabMedicineAcute coronary syndromeStatinInternal medicineMonoclonalLDL receptorPharmacologyMonoclonal antibodyCholesterolAntibodyImmunologyLipoproteinMyocardial infarctionApolipoprotein A1Lipoproteins and Cardiovascular HealthPharmaceutical Economics and Policy